FAST NEWS: Simcere’s Covid drug trial shows promising results
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that newly published results of a Phase 2/3 clinical study for its innovative drug, Xiannuoxin, for the treatment of adult patients…
FAST NEWS: Simcere gets exclusive rights to innovative influenza drug
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Tuesday that it has signed a deal giving it exclusive commercialization rights for treatment of influenza indications using the innovative drug ADC189 from Jiaxing…
FAST NEWS: Simcere’s revenue jumps on rising innovative drug sales
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday it expects to report its revenue grew between 24% and 26.3% to between 3.35 billion yuan ($468 million) and 3.41 billion yuan in…
Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases
Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…
RELATED ARTICLES
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Everest reaches new heights on growing drug sales
1952.HK
